Antibody-based detection of erg rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies

Archives of Pathology and Laboratory Medicine

Volumn 136, Issue 8, 2012, Pages 935-946

  Tomlins, Scott A ^a   Palanisamy, Nallasivam ^a   Siddiqui, Javed ^a   Chinnaiyan, Arul M ^a,b   Kunju, Lakshmi P ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERG PROTEIN, HUMAN; ONCOPROTEIN; TRANSACTIVATOR PROTEIN;

AGED; ANTIBODY SPECIFICITY; CANCER GRADING; COHORT ANALYSIS; CONFERENCE PAPER; EPITHELIUM; EVALUATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; NEEDLE BIOPSY; PATHOLOGY; PROSPECTIVE STUDY; PROSTATE; PROSTATE TUMOR; PROSTATIC INTRAEPITHELIAL NEOPLASIA; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

AGED; ANTIBODY SPECIFICITY; BIOPSY, NEEDLE; COHORT STUDIES; EPITHELIUM; GENE REARRANGEMENT; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; NEOPLASM GRADING; ONCOGENE PROTEINS, FUSION; PROSPECTIVE STUDIES; PROSTATE; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TRANS-ACTIVATORS;

EID: 84865013222     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2011-0424-OA     Document Type: Conference Paper

References (31)

1. Van der Kwast TH, Evans A, Lockwood G, et al. Variability in diagnostic opinion among pathologists for single small atypical foci in prostate biopsies [published correction appears in Am J Surg Pathol. 2010;34(5):688]. Am J Surg Pathol. 2010;34(2);169-177.
2. Epstein JI, Herawi M. Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: Implications for patient care. J Urol. 2006;175(3, pt 1);820-834. (Pubitemid 43199991)
3. Epstein JI. Precursor lesions to prostatic adenocarcinoma. Virchows Arch. 2009;454(1);1-16.
4. Kunju LP, Chinnaiyan AM, Shah RB. Comparison of monoclonal antibody (P504S) and polyclonal antibody to alpha methylacyl-CoA racemase (AMACR) in the work-up of prostate cancer. Histopathology. 2005;47(6);587-596. (Pubitemid 41775181)
5. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310(5748); 644-648. (Pubitemid 41528150)
6. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat Rev Cancer. 2008;8(7);497-511.
7. Tomlins SA, Bjartell A, Chinnaiyan AM, et al. ETS gene fusions in prostate cancer: From discovery to daily clinical practice. Eur Urol. 2009;56(2);275-286.
8. Han B, Mehra R, Dhanasekaran SM, et al. A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: Identification of DDX5-ETV4 fusion protein in prostate cancer. Cancer Res. 2008;68(18); 7629-7637.
9. Pflueger D, Rickman DS, Sboner A, et al. N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer. Neoplasia. 2009;11(8);804-811.
10. Furusato B, Tan SH, Young D, et al. ERG oncoprotein expression in prostate cancer: Clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer Prostatic Dis. 2010;13(3);228-237.
11. Park K, Tomlins SA, Mudaliar KM, et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia. 2010;12(7);590-598.
12. Barry M, Perner S, Demichelis F, Rubin MA. TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: Clinical and biologic implications. Urology. 2007;70(4);630-633. (Pubitemid 350030260)
13. Furusato B, Gao CL, Ravindranath L, et al. Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer. Mod Pathol. 2008;21(2);67-75. (Pubitemid 351172158)
14. Mehra R, Han B, Tomlins SA, et al. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: Molecular evidence for an independent group of diseases. Cancer Res. 2007;67(17);7991-7995. (Pubitemid 47395131)
15. Svensson MA, LaFargue CJ, MacDonald TY, et al. Testing mutual exclusivity of ETS rearranged prostate cancer. Lab Invest. 2011;91(3);404-412.
16. Han B, Mehra R, Lonigro RJ, et al. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod Pathol. 2009;22(8);1083-1093.
17. Carver BS, Tran J, Gopalan A, et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet. 2009;41(5);619-624.
18. Mosquera JM, Perner S, Genega EM, et al. Characterization of TMPRSS2- ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications. Clin Cancer Res. 2008;14(11);3380-3385.
19. King JC, Xu J, Wongvipat J, et al. Cooperativity of TMPRSS2-ERG with PI3- kinase pathway activation in prostate oncogenesis. Nat Genet. 2009;41(5);524-526.
20. Zong Y, Xin L, Goldstein AS, Lawson DA, Teitell MA, Witte ON. ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells. Proc Natl Acad Sci U S A. 2009;106(30);12465-12470.
21. Setlur SR, Mertz KD, Hoshida Y, et al. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst. 2008;100(11);815-825. (Pubitemid 351809667)
22. Tomlins SA, Mehra R, Rhodes DR, et al. Integrative molecular concept modeling of prostate cancer progression. Nat Genet. 2007;39(1);41-51. (Pubitemid 46026500)
23. van Leenders GJ, Boormans JL, Vissers CJ, et al. Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: Implications for pathological practice. Mod Pathol. 2011;24(8);1128-1138.
24. He H, Magi-Galluzzi C, Li J, et al. The diagnostic utility of novel immunohistochemical marker ERG in the workup of prostate biopsies with "atypical glands suspicious for cancer." Am J Surg Pathol. 2011;35(4);608-614.
25. Yaskiv O, Zhang X, Simmerman K, et al. The utility of ERG/P63 double immunohistochemical staining in the diagnosis of limited cancer in prostate needle biopsies. Am J Surg Pathol. 2011;35(7);1062-1068.
26. Sato Y. Role of ETS family transcription factors in vascular development and angiogenesis. Cell Struct Funct. 2001;26(1);19-24. (Pubitemid 32421948)
27. Albadine R, Latour M, Toubaji A, et al. TMPRSS2-ERG gene fusion status in minute (minimal) prostatic adenocarcinoma. Mod Pathol. 2009;22(11);1415- 1422.
28. Zhang S, Pavlovitz B, Tull J, Wang Y, Deng FM, Fuller C. Detection of TMPRSS2 gene deletions and translocations in carcinoma, intraepithelial neoplasia, and normal epithelium of the prostate by direct fluorescence in situ hybridization. Diagn Mol Pathol. 2010;19(3);151-156.
29. Beach R, Gown AM, De Peralta-Venturina MN, et al. P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies. Am J Surg Pathol. 2002;26(12);1588-1596. (Pubitemid 35387221)
30. Kunju LP, Rubin MA, Chinnaiyan AM, Shah RB. Diagnostic usefulness of monoclonal antibody P504S in the workup of atypical prostatic glandular proliferations. Am J Clin Pathol. 2003;120(5);737-745. (Pubitemid 37339682)
31. Przybycin CG, Kunju LP, Wu AJ, Shah RB. Partial atrophy in prostate needle biopsies: A detailed analysis of its morphology, immunophenotype, and cellular kinetics. Am J Surg Pathol. 2008;32(1);58-64.